STM JOURNALS

Research & Reviews: A Journal of
Drug Formulation, Development and Production

ISSN: 2394-1944
Volume 12, Issue 1, 2025
January–April
DOI (Journal): 10.37591/RRJoDFDP

https://journals.stmjournals.com/rrjodfdp

Review RRJoDFDP

Molecular Mechanisms of Drug Metabolism in Anesthesia: A Pharmacogenomic Perspective

Tehseen Irshad[1,*], Bilal[2], Sowby Jan[1]

Abstract

Pharmacogenomics studies how a person's genetic profile affects their reaction to drugs, which is vital in anesthesia. Anesthetic pharmacology depends significantly on drug metabolism, which involves complex biochemical processes that manage the absorption, distribution, metabolism, and excretion (ADME) of anesthetic drugs. The cytochrome P450 (CYP) enzyme family plays a critical role in the metabolism of various anesthetic drugs, with genetic polymorphisms leading to inter-individual variability in drug responses. Specific CYP enzymes, such as CYP2D6, CYP3A4, and CYP2C19 have been identified as key players in the metabolism of anesthetics like opioids, volatile agents, and intravenous anesthetics. Variations in these enzymes can result in poor, intermediate, extensive, or ultra-rapid metabolism, affecting the efficacy and safety of medications. Single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) in genes encoding drug-metabolizing enzymes influence the pharmacokinetics and pharmacodynamics of anesthetic agents. For example, CYP2D6 polymorphisms impact opioid metabolism, affecting pain management and increasing the risk of adverse reactions, such as respiratory depression. Similarly, CYP3A4 variability alters the metabolism of benzodiazepines and other anaesthetics, leading to differences in sedation levels and recovery times. Understanding these genetic differences allows anaesthesiologists to tailor aesthetic regimens, optimizing dosing strategies and minimizing adverse effects. Progress in genetic testing methods, including polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray analysis, has made it easier to identify genetic variants associated with drug metabolism. Ethical considerations, including informed consent, data privacy, and the prevention of genetic discrimination, are essential when implementing pharmacogenomic testing in clinical practice. Incorporating pharmacogenomics into anesthetic practice offers the potential to enhance patient outcomes through personalized medicine.

Keywords: Pharmacogenomics, Cytochrome P450, drug metabolism, anesthesia, genetic polymorphisms

***Author for Correspondence**
Tehseen Irshad
E-mail: mirtehseen03@gmail.com

[1]Assistant Professor, St. Soldier Group of Institutions, Jalandhar, Punjab, India.
[2]Anaesthesiologist, Government Medical College (GMC), and Associated Hospital, Baramulla, Jammu & Kashmir, India

Received Date: February 06, 2025
Accepted Date: March 08, 2025
Published Date: April 04, 2025

Citation: Tehseen Irshad, Bilal, Sowby Jan. Molecular Mechanisms of Drug Metabolism in Anesthesia: A Pharmacogenomic Perspective. Research and Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(1): 90–95p.

INTRODUCTION

Pharmacogenomics combines pharmacology with genomics to develop safe and effective medications tailored to a person's genetic makeup. In anesthetic practice, grasping the molecular mechanisms of drug metabolism is crucial for improving patient care. The cytochrome P450 (CYP) enzyme system is crucial in drug metabolism via enzymatic activities. It investigates how a person's genetic profile affects their response to medications [1]. This emerging field combines pharmacology, the study of drugs, with genomics, which examines gene structure and function. The aim is to develop

personalized treatments that are both safe and effective based on an individual's genetic profile. Pharmacogenomics is vital for transforming healthcare by providing personalized treatment approaches that improve drug effectiveness and reduce adverse effects [2]. Unlike the traditional one-size-fits-all approach, pharmacogenomics promotes individualized care, enabling healthcare providers to prescribe medications with greater accuracy and predictability. It provides insights into why some individuals respond well to specific drugs while others do not, and why certain people experience severe side effects. By integrating genetic information into clinical decision-making, providers can optimize drug selection and dosage, ultimately improving patient outcomes [3].

HISTORICAL BACKGROUND AND PROGRESSION OF PHARMACOGENOMICS

Although the concept of personalized medicine is longstanding, the integration of genetic science into pharmacology gained momentum in the late 20th century. In the 1950s, researchers first identified that genetic differences could impact drug metabolism, leading to the discovery of pharmacogenetic variants. A significant example is the association between genetic variations in the glucose-6-phosphate dehydrogenase enzyme and negative reactions to antimalarial medications. The completion of the Human Genome Project in 2003 marked a turning point, offering a detailed map of the human genome and facilitating breakthroughs in pharmacogenomics. This achievement accelerated the identification of genetic factors influencing drug responses. Progress in high-throughput sequencing and bioinformatics has broadened the field, enabling large-scale genetic analysis. Over the past twenty years, pharmacogenomics has transitioned from a specialized research area to a key component of clinical practice across various medical disciplines [4]. The use of genetic testing to assess drug metabolism and response has become increasingly common, with pharmacogenomic data now playing a significant role in clinical guidelines and treatment decisions.

GENETIC VARIATION AND DRUG

Genetic polymorphisms refer to variations in DNA sequences that are found among individuals within a population [5]. These differences can affect how people react to medications, including their effectiveness and the likelihood of negative side effects. Polymorphisms can be found in various regions of the genome, including coding regions of genes, regulatory regions, and non-coding regions. They can affect gene function in multiple ways, such as altering protein structure, changing gene expression levels, or modifying regulatory mechanisms.

Differences in enzymes that metabolize drugs, transporters of drugs, and drug targets are particularly important in pharmacogenomics. For example, variations in the CYP450 enzyme family can result in different metabolic types, including poor, intermediate, extensive, or ultra-rapid metabolizers. These phenotypes can significantly impact the pharmacokinetics and pharmacodynamics of many drugs used in anesthesia, influencing both their efficacy and safety.

MECHANISMS OF DRUG METABOLISM

Drug metabolism is a crucial biochemical procedure that transforms medications into variants that the body can more readily excrete. It takes place mainly in the liver and includes two main stages: phase I and phase II reactions [6].

Phase I reactions are mainly facilitated by cytochrome P450 (CYP) enzymes and encompass oxidation, reduction, and hydrolysis. These reactions add or reveal functional groups, like hydroxyl (-OH) or amino (-NH2), which typically lead to the activation or inactivation of the drug. Oxidation, the most common phase I reaction, is responsible for making drugs more water-soluble, facilitating their further metabolism or excretion.

CYP enzymes, especially CYP3A4, CYP2D6, and CYP2C9, are crucial for metabolizing various medications, such as antidepressants, anticoagulants, and beta-blockers. Variations in these enzymes due to genetic polymorphisms can alter drug metabolism rates, influencing both drug effectiveness and toxicity [7].

Phase II reactions, or conjugation reactions, increase drug solubility by linking endogenous molecules like glucuronic acid, sulfate, or glutathione to the drug or its Phase I metabolite. Processes, such as glucuronidation, sulfation, acetylation, and methylation significantly increase the hydrophilicity of drugs, promoting their renal or biliary excretion. Phase II metabolism generally results in the detoxification of drugs, making them less active and easier to eliminate from the body. Genetic variations in phase II enzymes, such as UGT1A1 and NAT2, can influence drug response and the risk of adverse effects, underscoring the importance of pharmacogenomics in individualized therapy [8].

Role of Cytochrome P450 Enzymes

The cytochrome P450 (CYP) enzymes are a family of heme-containing monooxygenases that play a critical role in the metabolism of a wide variety of drugs, including many anesthetics. These enzymes are mainly located in the liver, but they can also be found in various other tissues.

They are involved in phase I metabolism, where they catalyze the oxidation, reduction, and hydrolysis of drugs, facilitating their subsequent elimination [9].

The CYP450 enzymes exhibit significant genetic variability, with numerous polymorphisms affecting their activity. These genetic differences can lead to substantial interindividual variability in drug metabolism. Key CYP enzymes relevant to anesthesia include CYP3A4, CYP2D6, CYP2C9, and CYP2C19.

Genetic Variations in Drug-Metabolizing Enzymes

- CYP2D6 The CYP2D6 enzyme metabolizes approximately 25% of all clinically used drugs, including opioids (e.g., codeine, tramadol), beta-blockers (e.g., metoprolol), and antidepressants (e.g., fluoxetine). Genetic polymorphisms in CYP2D6 can result in four distinct metabolic phenotypes: poor, intermediate, extensive, and ultra-rapid metabolizers. Poor metabolizers have little to no CYP2D6 activity, leading to reduced drug clearance and increased risk of adverse effects. In contrast, ultra-rapid metabolizers possess several copies of the CYP2D6 gene, leading to swift drug metabolism and possibly diminished therapeutic effectiveness.
- CYP2C19 The CYP2C19 enzyme is involved in the metabolism of several important drugs, including proton pump inhibitors (e.g., omeprazole), antiplatelet agents (e.g., clopidogrel), and certain antidepressants (e.g., citalopram). Polymorphisms in CYP2C19, such as CYP2C192 and CYP2C193, lead to reduced enzyme activity and can impact drug response. For instance, individuals who are poor metabolizers of CYP2C19 may exhibit reduced activation of clopidogrel, leading to a weaker antiplatelet effect and a higher risk of cardiovascular events.
- CYP2C9 The CYP2C9 enzyme metabolizes drugs, such as warfarin, phenytoin, and NSAIDs (e.g., ibuprofen). Polymorphisms, like CYP2C92 and CYP2C93, are associated with reduced enzyme activity, affecting drug clearance and necessitating dose adjustments to avoid toxicity.
- CYP3A4 CYP3A4 is one of the most abundant and versatile CYP enzymes, metabolizing a broad range of drugs, including many anesthetics, benzodiazepines, and statins. Genetic variability in CYP3A4 can influence drug metabolism, although the impact is often less pronounced compared to CYP2D6 and CYP2C19 due to the presence of compensatory mechanisms [10].

EVIDENCE LINKING ANESTHETIC METABOLISM TO NEPHROTOXICITY

Historically, inhalational anesthetics were considered pharmacologically active yet metabolically inert. However, Van Dyke and colleagues were the first to demonstrate the biotransformation of diethyl ether, chloroform, and halothane, revealing that all volatile anesthetics undergo metabolism. The association between anesthetic metabolism and nephrotoxicity was initially suspected when elevated inorganic fluoride levels, a metabolite of methoxyflurane, were observed in patients who developed renal dysfunction post-anesthesia [11].

Subsequent research by Mazze and colleagues established a correlation between nephrotoxicity and inorganic fluoride concentrations, with adverse effects noted at levels above 50 μM and clinical

nephrotoxicity becoming evident within the range of 80–175 μM. Further studies examined urinary concentrating ability following exposure to other fluorinated agents, such as isoflurane and enflurane. While isoflurane metabolism results in minimal fluoride production and does not impair concentrating ability, enflurane exposure was associated with a transient, clinically insignificant reduction in renal function when fluoride levels peaked at 34 μM.

Animal studies using Fischer 344 rats provided further insights into the nephrotoxic potential of anesthetic metabolism. These studies demonstrated that methoxyflurane exposure, or direct inorganic fluoride administration, led to vasopressin-resistant polyuric renal insufficiency. Additionally, pretreatment with phenobarbital, an enzyme inducer, resulted in elevated fluoride levels and more severe nephrotoxicity, while enzyme inhibition with SKF 525A reduced fluoride concentrations and renal damage. Findings indicated that inorganic fluoride is the principal nephrotoxic metabolite rather than oxalic acid, which only caused nephrotoxicity at significantly higher doses than typically encountered during methoxyflurane anesthesia.

ROLE OF ENZYME INDUCTION IN ANESTHETIC NEPHROPATHY

Volatile anesthetics are metabolized by microsomal enzyme systems, including cytochrome P450, which is known to be induced by various compounds commonly encountered by surgical patients. Enzyme induction enhances the defluorination of anesthetics, increasing the risk of nephrotoxicity. Research by Cousins et al. demonstrated that phenobarbital-treated rats exposed to methoxyflurane exhibited higher fluoride levels and more severe renal damage compared to controls. However, similar treatment did not enhance the metabolism or nephrotoxic potential of isoflurane, suggesting that factors, such as the drug's solubility and excretion rates play a role [12].

Comparative studies by Mazze et al. revealed that phenobarbital pretreatment significantly increased methoxyflurane metabolism and nephrotoxicity but did not have the same effect on isoflurane. In vitro, phenobarbital treatment led to a substantial increase in the enzymatic defluorination of methoxyflurane but had a relatively lower effect on isoflurane, likely due to differences in drug solubility and clearance rates.

Studies with other anesthetics, such as enflurane and sevoflurane further supported the hypothesis that substrate availability rather than enzyme induction limits metabolism in vivo. While enflurane metabolism remained unaffected by enzyme induction, sevoflurane metabolism was significantly increased in phenobarbital-treated rats, leading to a rise in urinary fluoride excretion [13].

Influence of Inducing Agents

Most studies have focused on phenobarbital as an enzyme inducer, assuming a uniform metabolic response across volatile anesthetics. However, data indicate variability in the effects of enzyme induction. Preliminary findings suggest that 3-methylcholanthrene does not influence methoxyflurane metabolism, whereas phenytoin exhibits effects comparable to phenobarbital in enhancing fluoride production and nephrotoxicity [14–15].

CLINICAL IMPLICATIONS IN HUMANS

Human studies have shown variability in anesthetic metabolism and fluoride production, potentially due to enzyme induction from prior drug treatments. For instance, one patient exhibited an unusually high peak fluoride concentration following enflurane anesthesia, which was attributed to concurrent medication use. Although definitive clinical data are lacking, animal studies suggest that methoxyflurane nephrotoxicity could be exacerbated in enzyme-induced patients, whereas enflurane and isoflurane metabolism may remain relatively unaffected, posing minimal nephrotoxic risk. Additional research is crucial to comprehend the clinical impact of enzyme induction on anesthetic-related nephrotoxicity.

Methodologies Techniques for Genetic Testing

- Polymerase Chain Reaction (PCR) is a commonly employed method for amplifying DNA sequences enable the detection of genetic variations. PCR-based techniques can detect known SNPs, indels, and various genetic changes. Methods, like allele-specific PCR and real-time PCR, are frequently employed in pharmacogenomic testing.
- DNA Sequencing DNA sequencing methods, including Sanger sequencing and next-generation sequencing (NGS), allow for the comprehensive analysis of genetic variations.
- NGS can sequence entire genomes or targeted regions, providing detailed information on genetic polymorphisms that may affect drug response.
- Microarray Analysis Microarrays are used to detect multiple genetic variations simultaneously. This technique involves hybridizing DNA samples to a chip containing probes for specific SNPs or other genetic markers. Microarrays are useful for screening large populations for pharmacogenomic variants.
- Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) offer extensive genetic information by analyzing either all coding regions or the complete genome, respectively. These methods can detect both known and new genetic variants that may affect drug metabolism and response.

CONCLUSIONS

A thorough understanding of the molecular mechanisms underlying drug metabolism in anesthesia through pharmacogenomics paves the way for precision medicine, optimizing drug selection and dosing for each patient. Utilizing genetic insights enables healthcare providers to reduce adverse effects, improve drug effectiveness, and enhance patient safety. The ongoing progress of studies in this area, along with the broad adoption of genetic testing, will enhance personalized anesthetic management even more. As pharmacogenomic data is increasingly incorporated into clinical guidelines, it has the potential to transform anesthetic care by providing personalized treatment approaches that optimize benefits and minimize risks.

REFERENCES

1. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015 Jan;25(1):33–41. doi: 10.1016/j.tcm.2014.09.001.
2. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004 Sep;5(9):669–76. doi: 10.1038/nrg1428
3. Flockhart DA. Cytochrome P450 Drug Interaction Table. Clin Pharmacol Ther. 2007;81(1):45–49.
4. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487–491.
5. Gage BF, Lesko LJ. Pharmacogenetics and coumarin therapy: ready for prime time? Clin Pharmacol Ther. 2008;84(3):365–369.
6. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Ann Rev Pharmacol Toxicol. 2015;55:89–106.
7. Kitzmiller JP, Groen DK, Phelps MA, Sadee W, Gianella-Borradori A. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleveland Clin J Med. 2011;78(4):243–257.
8. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA. 2001;286(18):2270–2279.
9. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Ann Rev Pharmacol Toxicol. 2001;41(1):101–121.
10. Roden DM, George Jr, AL. The genetic basis of variability in drug responses. Nat Rev Drug Discovery. 2002;1(1):37–44.
11. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–287.

12. McCaffery K, Holmes-Rovner M. Self-reported outcome measures of the shared decision-making process: A systematic review. Med Decision Making. 2009;30(2):144–158.
13. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. New Eng J Med. 2009;360(8):753–764.
14. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Derijks HJ, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673.
15. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. JAMA. 1973 Sep 24;225(13):1611–6. doi: 10.1001/jama.225.13.1611

